Obsidian Therapeutics will present updated Phase 1/2 data on amsoki-cel (OBX-115) in advanced melanoma at the SITC 2026 Annual Meeting, the company announced via Business Wire.

Amsoki-cel is an engineered tumor-infiltrating lymphocyte (TIL) product candidate in development for patients with advanced melanoma. The upcoming presentation will add to the existing Phase 1/2 dataset for the investigational cell therapy.

The Society for Immunotherapy of Cancer (SITC) Annual Meeting serves as one of the principal scientific forums for cancer immunotherapy data, and melanoma has long been a central indication for TIL-based approaches. Presentation at the 2026 meeting will give dermatologic oncologists and immuno-oncology investigators a fuller view of how the candidate is performing in the clinic.

The company did not disclose additional trial results in the announcement; the updated findings themselves are expected at the meeting. Specific details on response rates, durability, dosing, and the patient cohort will accompany the presentation.

For dermatologists who manage advanced melanoma patients, TIL therapy represents a distinct treatment modality from checkpoint inhibitors and targeted therapies. Whether amsoki-cel can carve out a role in the post-immunotherapy setting will depend on the strength of the updated efficacy and safety data — answers the field now awaits at SITC 2026.